Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 8/20 | 0.49 |
| ▸ | RAB9A | P51151 | 8/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31068028 | 1.00 | HPGD (0.53) | HPGDMAPTALDH1A1HDAC3HDAC4 | |
| SCHEMBL27983454 | 0.84 | PRKCI (0.48) | HPGDMAPTALDH1A1HDAC3HDAC4 | |
| SCHEMBL27293915 | 0.83 | MAPT (0.56) | HPGDMAPTALDH1A1HDAC3HDAC4 | |
| SCHEMBL193423 | 0.81 | MAPT (0.59) | HPGDMAPTALDH1A1HDAC3HDAC4 | |
| SCHEMBL6531550 | 0.81 | MAPT (0.54) | HPGDMAPTALDH1A1HDAC3HDAC4 | |
| SCHEMBL30390410 | 0.81 | MAPT (0.59) | HPGDMAPTALDH1A1HDAC3HDAC4 | |
| Hydrochloric Acid SCHEMBL548656 | 0.79 | MAPT (0.57) | HPGDMAPTALDH1A1HDAC3HDAC4 | |
| SCHEMBL30134133 | 0.79 | NPC1 (0.54) | HPGDMAPTALDH1A1HDAC3HDAC4 | |
| Lithium Ion SCHEMBL31133341 | 0.79 | MAPT (0.57) | HPGDMAPTALDH1A1HDAC3HDAC4 | |
| SCHEMBL28612277 | 0.79 | MAPT (0.57) | HPGDMAPTALDH1A1HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709479-A1 | 6,6-FUSED BICYCLIC AMIDES AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | Amgen Inc. (US) | 2026-03-18 | — | — | EP | claimed |
| EP-3227271-B1 | HETEROCYCLIC DERIVATIVES AND USE THEREOF | C&C RES LAB (KR) | 2025-08-13 | — | — | EP | claimed |
| WO-2024233563-A1 | 6,6-FUSED BICYCLIC AMIDES AND COMPOSITIONS FOR USE AS 15-PROSTAGLANDIN DEHYDROGENASE MODULATORS | AMGEN INC. (US) | 2024-11-14 | — | — | WO | claimed |
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2023-06-22 | — | — | US | claimed |
| EP-4081299-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2022-11-02 | — | — | EP | claimed |
| CN-114867525-A | Dihydrocyclopentaisoquinoline derivatives | UCB生物制药有限责任公司 | 2022-08-05 | — | — | CN | claimed |
| WO-2021130255-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | UCB Biopharma SRL (BE) | 2021-07-01 | — | — | WO | claimed |
| CN-107108534-A | Probes for Imaging Huntingtin | CHDI基金会股份有限公司 | 2017-08-29 | — | — | CN | claimed |
| CN-107001345-A | Hete rocyclic derivatives and application thereof | 株式会社C&C新药研究所 | 2017-08-01 | — | — | CN | claimed |
| CN-103764140-B | Indanone derivatives, pharmaceutically acceptable salts or optical isomers thereof, preparation method for same, and pharmaceutical compositions containing same as active ingredient for preventing or treating viral diseases | 韩国化学研究院 | 2017-05-17 | — | — | CN | claimed |
| WO-2013000924-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-03 | — | — | WO | claimed |
| CN-101616919-B | Poly (ADP ribose) polymerase inhibitors | ABBOTT LAB | 2012-10-10 | — | — | CN | claimed |
| CN-102153562-A | Spiro-oxindole compounds and their uses as therapeutic agents | XENON PHARMACEUTICALS INC | 2011-08-17 | — | — | CN | claimed |
| CN-101184761-A | Spiro-indolone compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC (CA) | 2008-05-21 | — | — | CN | claimed |
| EP-1828147-A1 | QUINOXALINES AS B-RAF INHIBITORS | AstraZeneca AB (SE) | 2007-09-05 | — | — | EP | claimed |
| CN-1809563-A | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents | CHIRON CORP (US) | 2006-07-26 | — | — | CN | claimed |
| WO-2006040568-A1 | QUINOXALINES AS B RAF INHIBITORS | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | claimed |
| WO-2004019933-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | claimed |
| EP-1363897-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2003-11-26 | — | — | EP | claimed |
| WO-2002070509-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-09-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192646-A1 | DIHYDRO-CYCLOPENTA-ISOQUINOLINE DERIVATIVES | FCER2, FCGR2A, FCGR1A | HPGD 253/4885MAPT 4114/4885ALDH1A1 1433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.